3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Liver Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Virus Diseases
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Melanoma
1
Laryngeal Neoplasms
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
Dexamethasone
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tislelizumab
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
lortalamine
1
gossypol acetic acid
1
daratumumab
1
aflibercept
1
Prednisone
1
Oncolytic Virotherapy
1
Octreotide
1
Mitomycin
1
Mammography
1
Lenalidomide
1
Ipilimumab
1
Drug Delivery Systems
1
Docetaxel
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
Bevacizumab
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled